Exhibit 99.1

UNITED STATES BANKRUPTCY COURT

      DISTRICT OF DELAWARE

 

                    

 

In Re. SANGAMO THERAPEUTICS, INC.   §   Case No. 26-10989
  §  
                        §  
Debtor(s)   §  
    ☐ Jointly Administered

 

Amended Monthly Operating Report         Chapter 11
Reporting Period Ended: 07/31/2026     Petition Date:    06/23/2026        
Months Pending: 1        Industry Classification:  LOGO
Reporting Method:    Accrual Basis LOGO    Cash Basis LOGO
Debtor’s Full-Time Employees (current):    73      
Debtor’s Full-Time Employees (as of date of order for relief):    74      

 

Supporting Documentation (check all that are attached):

(For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor)

 

☒

Statement of cash receipts and disbursements

☒

Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit

☒

Statement of operations (profit or loss statement)

 

☐

Accounts receivable aging

 

☐

Postpetition liabilities aging

 

☐

Statement of capital assets

 

☐

Schedule of payments to professionals

 

☒

Schedule of payments to insiders

☒

All bank statements and bank reconciliations for the reporting period

☐

Description of the assets sold or transferred and the terms of the sale or transfer

 

/s/ Nikunj Jain

    

Nikunj Jain

Signature of Responsible Party      Printed Name of Responsible Party

10/23/2026

    
Date     
    

501 Canal Blvd., Suite A100 Richmond, CA 94804

     Address

 

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. §1320.4(a)(2) applies.

 

UST Form 11-MOR (12/01/2021)    1   

Docket No. 537

Filed: 10/23/26


Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

Part 1: Cash Receipts and Disbursements

   Current Month      Cumulative  
a.    Cash balance beginning of month    $ 14,382,244     
     

 

 

    
b.    Total receipts (net of transfers between accounts)    $ 18,058,990      $ 28,562,062  
     

 

 

    

 

 

 
c.    Total disbursements (net of transfers between accounts)    $ 15,534,279      $ 16,512,210  
     

 

 

    

 

 

 
d.    Cash balance end of month (a+b-c)    $ 16,906,955     
     

 

 

    
e.    Disbursements made by third party for the benefit of the estate    $ 0      $ 0  
     

 

 

    

 

 

 
f.    Total disbursements for quarterly fee calculation (c+e)    $ 15,534,279      $ 16,512,210  
     

 

 

    

 

 

 

Part 2: Asset and Liability Status

(Not generally applicable to Individual Debtors. See Instructions.)

   Current Month         
a.    Accounts receivable (total net of allowance)    $ 500,160     
     

 

 

    
b.    Accounts receivable over 90 days outstanding (net of allowance)    $ 90,355     
     

 

 

    
c.    Inventory (Book  LOGO  Market  LOGO  Other  LOGO  (attach explanation))    $ 0     
     

 

 

    
d    Total current assets    $ 20,386,655     
     

 

 

    
e.    Total assets    $ 155,117,944     
     

 

 

    
f.    Postpetition payables (excluding taxes)    $ 18,768,593     
     

 

 

    
g.    Postpetition payables past due (excluding taxes)    $ 366,473     
     

 

 

    
h.    Postpetition taxes payable    $ 269,455     
     

 

 

    
i.    Postpetition taxes past due    $ 0     
     

 

 

    
j.    Total postpetition debt (f+h)    $ 19,038,048     
     

 

 

    
k.    Prepetition secured debt    $ 0     
     

 

 

    
l.    Prepetition priority debt    $ 32,543     
     

 

 

    
m.    Prepetition unsecured debt    $ 78,061,802     
     

 

 

    
n.    Total liabilities (debt) (j+k+l+m)    $ 97,132,393     
     

 

 

    
o.    Ending equity/net worth (e-n)    $ 57,985,551     
     

 

 

    

Part 3: Assets Sold or Transferred

   Current Month      Cumulative  
a.    Total cash sales price for assets sold/transferred outside the ordinary course of business    $ 0      $ 0  
     

 

 

    

 

 

 
b.    Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business    $ 0      $ 0  
     

 

 

    

 

 

 
c.    Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b)    $ 0      $ 0  
     

 

 

    

 

 

 

Part 4: Income Statement (Statement of Operations)

(Not generally applicable to Individual Debtors. See Instructions.)

   Current Month      Cumulative  
a.    Gross income/sales (net of returns and allowances)    $ 720,000     
     

 

 

    
b.    Cost of goods sold (inclusive of depreciation, if applicable)    $ 0     
     

 

 

    
c.    Gross profit (a-b)    $ 720,000     
     

 

 

    
d.    Selling expenses    $ 0     
     

 

 

    
e.    General and administrative expenses    $ 3,764,872     
     

 

 

    
f.    Other expenses    $ 3,231,570     
     

 

 

    
g.    Depreciation and/or amortization (not included in 4b)    $ 216,290     
     

 

 

    
h.    Interest    $ 105,000     
     

 

 

    
i.    Taxes (local, state, and federal)    $ 0     
     

 

 

    
j.    Reorganization items    $ 4,244,225     
     

 

 

    
k.    Profit (loss)    $ -11,165,298      $ -14,920,356  
     

 

 

    

 

 

 

 

UST Form 11-MOR (12/01/2021)   2  


Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

Part 5: Professional Fees and Expenses

 

 

 

a. 

         Approved
Current Month
   Approved
Cumulative
   Paid Current
Month
     Paid
Cumulative
 
   Debtor’s professional fees & expenses (bankruptcy) Aggregate Total                            
   Itemized Breakdown by Firm              
        Firm Name    Role
   i                                      
   ii                                      
   iii                                      
   iv                                      
   v                                      
   vi                                      
   vii                                      
   viii                                      
   ix                                      
   x                                      
   xi                                      
   xii                                      
   xiii                                      
   xiv                                      
   xv                                      
   xvi                                      
   xvii                                      
   xviii                                      
   xix                                      
   xx                                      
   xxi                                      
   xxii                                      
   xxiii                                      
   xxiv                                      
   xxv                                      
   xxvi                                      
   xxvii                                      
   xxviii                                      
   xxix                                      
   xxx                                      
   xxxi                                      
   xxxii                                      
   xxxiii                                      
   xxxiv                                      
   xxxv                                      
   xxxvi                                      

 

UST Form 11-MOR (12/01/2021)   3  


Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

     xxxvii                              
   xxxviii                                      
   xxxix                              
   xl                              
   xli                              
   xlii                              
   xliii                              
   xliv                              
   xlv                              
   xlvi                              
   xlvii                              
   xlviii                              
   xlix                              
   l                              
   li                              
   lii                              
   liii                              
   liv                              
   lv                              
   lvi                              
   lvii                              
   lviii                              
   lix                              
   lx                              
   lxi                              
   lxii                              
   lxiii                              
   lxiv                              
   lxv                              
   lxvi                              
   lxvii                              
   lxviii                              
   lxix                              
   lxx                              
   lxxi                              
   lxxii                              
   lxxiii                              
   lxxiv                              
   lxxv                              
   lxxvi                              
   lxxvii                              
   lxxviii                              

 

UST Form 11-MOR (12/01/2021)   4  


Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

     lxxix                                      
   lxxx                                      
   lxxxi                                      
   lxxxii                                      
   lxxxiii                                      
   lxxxiv                                      
   lxxxv                                      
   lxxxvi                                      
   lxxxvii                                      
   lxxxviii                                      
   lxxxix                                      
   xc                                      
   xci                                      
   xcii                                      
   xciii                                      
   xciv                                      
   xcv                                      
   xcvi                                      
   xcvii                                      
   xcviii                                      
   xcix                                      
   c                                      
   ci                                      
                    

 

 

b. 

         Approved
Current Month
   Approved
Cumulative
   Paid Current
Month
     Paid
Cumulative
 
   Debtor’s professional fees & expenses (nonbankruptcy) Aggregate Total                $348        $348  
   Itemized Breakdown by Firm       
        Firm Name    Role
   i    Rothwell, Figg, Ernst & Manbec    Special Counsel                $295        $295  
   ii    Daijogo & Pedersen, LLP    Special Counsel                $ 52        $ 52  
   iii                                      
   iv                                      
   v                                      
   vi                                      
   vii                                      
   viii                                      
   ix                                      
   x                                      
   xi                                      
   xii                                      
   xiii                                      
   xiv                                      

 

UST Form 11-MOR (12/01/2021)   5  


Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

  

   xv                              
   xvi                                      
   xvii                              
   xviii                              
   xix                              
   xx                              
   xxi                              
   xxii                              
   xxiii                              
   xxiv                              
   xxv                              
   xxvi                              
   xxvii                              
   xxviii                              
   xxix                              
   xxx                              
   xxxi                              
   xxxii                              
   xxxiii                              
   xxxiv                              
   xxxv                              
   xxxvi                              
   xxxvii                              
   xxxviii                              
   xxxix                              
   xl                              
   xli                              
   xlii                              
   xliii                              
   xliv                              
   xlv                              
   xlvi                              
   xlvii                              
   xlviii                              
   xlix                              
   l                              
   li                              
   lii                              
   liii                              
   liv                              
   lv                              
   lvi                              

 

UST Form 11-MOR (12/01/2021)   6  


Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

  

   lvii                                      
   lviii                                              
   lix                                      
   lx                                      
   lxi                                      
   lxii                                      
   lxiii                                      
   lxiv                                      
   lxv                                      
   lxvi                                      
   lxvii                                      
   lxviii                                      
   lxix                                      
   lxx                                      
   lxxi                                      
   lxxii                                      
   lxxiii                                      
   lxxiv                                      
   lxxv                                      
   lxxvi                                      
   lxxvii                                      
   lxxviii                                      
   lxxix                                      
   lxxx                                      
   lxxxi                                      
   lxxxii                                      
   lxxxiii                                      
   lxxxiv                                      
   lxxxv                                      
   lxxxvi                                      
   lxxxvii                                      
   lxxxviii                                      
   lxxxix                                      
   xc                                      
   xci                                      
   xcii                                      
   xciii                                      
   xciv                                      
   xcv                                      
   xcvi                                      
   xcvii                                      
   xcviii                                      
   xcix                                      
               
     c                                      
         

c.   All professional fees and expenses (debtor & committees)

   $  0     $  0       $348        $348  

 

UST Form 11-MOR (12/01/2021)   7  


Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

Part 6: Postpetition Taxes

   Current Month      Cumulative  

a.   Postpetition income taxes accrued (local, state, and federal)

   $ 0      $ 0  
  

 

 

    

 

 

 

b.  Postpetition income taxes paid (local, state, and federal)

   $ 0      $ 0  
  

 

 

    

 

 

 

c.   Postpetition employer payroll taxes accrued

   $ 226,736      $ 282,175  
  

 

 

    

 

 

 

d.  Postpetition employer payroll taxes paid

   $ 421,834      $ 421,834  
  

 

 

    

 

 

 

e.   Postpetition property taxes paid

   $ 0      $ 0  
  

 

 

    

 

 

 

f.   Postpetition other taxes accrued (local, state, and federal)

   $ 39,582      $ 57,404  
  

 

 

    

 

 

 

g.  Postpetition other taxes paid (local, state, and federal)

   $ 0      $ 0  
  

 

 

    

 

 

 

 

Part 7: Questionnaire - During this reporting period:

                       

a.   Were any payments made on prepetition debt? (if yes, see Instructions)

   Yes    LOGO    No    LOGO  

b.  Were any payments made outside the ordinary course of business without court approval? (if yes, see Instructions)

   Yes    LOGO    No    LOGO  

c.   Were any payments made to or on behalf of insiders?

   Yes    LOGO    No    LOGO  

d.  Are you current on postpetition tax return filings?

   Yes    LOGO    No    LOGO  

e.   Are you current on postpetition estimated tax payments?

   Yes    LOGO    No    LOGO  

f.   Were all trust fund taxes remitted on a current basis?

   Yes    LOGO    No    LOGO  

g.  Was there any postpetition borrowing, other than trade credit? (if yes, see Instructions)

   Yes    LOGO    No    LOGO  

h.  Were all payments made to or on behalf of professionals approved by the court?

   Yes    LOGO    No    LOGO   N/A  LOGO

i.   Do you have:   Worker’s compensation insurance?

   Yes    LOGO    No    LOGO  

  If yes, are your premiums current?

   Yes    LOGO    No    LOGO   N/A  LOGO   (if no, see Instructions)

  Casualty/property insurance?

   Yes    LOGO    No    LOGO  

  If yes, are your premiums current?

   Yes    LOGO    No    LOGO   N/A  LOGO   (if no, see Instructions)

  General liability insurance?

   Yes    LOGO    No    LOGO  

  If yes, are your premiums current?

   Yes    LOGO    No    LOGO   N/A  LOGO   (if no, see Instructions)

j.   Has a plan of reorganization been filed with the court?

   Yes    LOGO    No    LOGO  

k.  Has a disclosure statement been filed with the court?

   Yes    LOGO    No    LOGO  

1.  Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930?

   Yes    LOGO    No    LOGO  

 

UST Form 11-MOR (12/01/2021)   8  


Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

Part 8: Individual Chapter 11 Debtors (Only)

                   

a.   Gross income (receipts) from salary and wages

            $   0
           

 

b.  Gross income (receipts) from self-employment

            $   0
           

 

c.   Gross income from all other sources

            $   0
           

 

d.  Total income in the reporting period (a+b+c)

            $   0
           

 

e.   Payroll deductions

            $   0
           

 

f.   Self-employment related expenses

            $   0
           

 

g.  Living expenses

            $   0
           

 

h.  All other expenses

            $   0
           

 

i.   Total expenses in the reporting period (e+f+g+h)

            $   0
           

 

j.   Difference between total income and total expenses (d-i)

            $   0
           

 

k.  List the total amount of all postpetition debts that are past due

            $   0
           

 

l.   Are you required to pay any Domestic Support Obligations as defined by 11 U.S.C § 101(14A)?

   Yes  LOGO    No  LOGO      

m.   If yes, have you made all Domestic Support Obligation payments?

   Yes  LOGO    No  LOGO    N/A  LOGO   

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor’s progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee’s or examiner’s duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee’s systems of records notice, UST-001, “Bankruptcy Case Files and Associated Records.” See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/ eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate.

 

/s/ Nikunj Jain

         

Nikunj Jain

Signature of Responsible Party       Printed Name of Responsible Party

Interim Chief Financial Officer

     

10/23/2026

Title       Date

 

UST Form 11-MOR (12/01/2021)   9  


Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

LOGO

PageOnePartOne PageOnePartTwo PageTwoPartOne PageTwoPartTwo

 

UST Form 11-MOR (12/01/2021)   10  


Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

LOGO

Bankruptcy1to50 Bankruptcy51to100 NonBankruptcy1to50 NonBankruptcy51to100

 

UST Form 11-MOR (12/01/2021)   11  


Debtor’s Name SANGAMO THERAPEUTICS, INC.    Case No. 26-10989

 

LOGO

PageThree PageFour

 

UST Form 11-MOR (12/01/2021)   12  


IN THE UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT DELAWARE

 

 
   )   
In re:    )    Chapter 11
   )   
SANGAMO THERAPEUTICS, INC.     )    Case No. 26-10989 (CTG)
   )   

Debtor.1

   )   

 

   )   

GLOBAL NOTES AND STATEMENT OF LIMITATIONS, METHODOLOGY, AND DISCLAIMERS REGARDING THE DEBTOR’S AMENDED2 MONTHLY OPERATING REPORT

 

On June 23, 2026 (the “Petition Date”), Sangamo Therapeutics, Inc. (the “Debtor”) commenced the above-captioned chapter 11 case by filing a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”) with the United States Bankruptcy Court for the District of Delaware (the “Court”). The Debtor is authorized to operate its business as a debtor-in-possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code.

General Methodology

The Debtor is filing its monthly operating report (the “MOR”) for the period from July 1, 2026 through July 31, 2026 (the “Reporting Period”) for purposes of complying with the monthly reporting requirements applicable in the Debtor’s chapter 11 case. The MOR is unaudited and has not been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and does not include all of the information and footnotes required by U.S. GAAP. The MOR is not intended to reconcile to any financial statements otherwise prepared or distributed by the Debtor. The MOR should not be relied upon by any persons for information relating to current or future financial condition, events, or performance of the Debtor or its affiliates, as the results of operations contained herein are not necessarily indicative of results which may be expected from any other period or for the full year and may not necessarily reflect the results of operations, financial position, and schedule of receipts and disbursements in the future.

 
1 

The Debtor and the last four digits of its taxpayer identification number are: Sangamo Therapeutics, Inc. (9556). The Debtor’s mailing address is 501 Canal Blvd., Ste A100, Richmond, CA 94804.

2 

This amended monthly operating report amends the July monthly operating report filed at Docket No. 427 to add information regarding payments inadvertently made to ordinary course professionals, as set forth in part 5(b) of the monthly operating report form and the attached attestation titled “Part 7(b) and 7(h) Payments Without Court Approval.”


Basis for Presentation

In preparing the MOR, the Debtor relied on financial information from its books and records at the time of such preparation. The financial information contained in the MOR is derived from the Debtor’s books and records without, among other things, all adjustments or reclassification that may be necessary or typical to accord with U.S. GAAP.

This information has not been subjected to procedures that would typically be applied to financial information presented in accordance with U.S. GAAP or any other recognized financial reporting framework. If such procedures were applied, the Debtor believes that the financial information presented in the MOR could be subject to change, including material change.

Although the Debtor made efforts to ensure the accuracy and completeness of the MOR, given the complexity of the Debtor’s business, inadvertent errors or omissions may occur. Accordingly, the Debtor hereby reserves all rights to dispute the nature, validity, status, enforceability, or executory nature of any claim amount, agreement, representation, or other statement set forth in the MOR. Further, the Debtor reserves the right to amend or supplement the MOR, if necessary, but shall be under no obligation to do so.

Moreover, given, among other things, the uncertainty surrounding the valuation and ownership of certain assets and the valuation and nature of certain liabilities, to the extent the Debtor shows more assets than liabilities, it is not an admission that the Debtor was solvent as of the Petition Date or at any time prior to the Petition Date. Likewise, to the extent the Debtor shows more liabilities than assets, it is not an admission that the Debtor was insolvent at the Petition Date or any time prior to the Petition Date.

For the reasons discussed above, there can be no assurance that the financial information presented in the MOR is complete, and readers are strongly cautioned not to place undue reliance on the MOR.

Each signatory to the MOR has necessarily relied upon the efforts, statements, advice, and representations of personnel of the Debtor and the Debtor’s advisors and professionals. Each signatory has not (and could not have) personally verified the accuracy of each such statement, representation, and answer contained in the MOR.

Reporting Period

Unless otherwise noted herein, the MOR generally reflects the Debtor’s books and records for the applicable Reporting Period. Unless otherwise noted herein, no adjustments have been made for activity occurring after the close of the Reporting Period.

Accuracy

The financial information disclosed in the MOR was not prepared in accordance with federal or state securities laws or other applicable non-bankruptcy law or in lieu of complying with any periodic reporting requirements thereunder. Persons and entities trading in or otherwise purchasing, selling, or transferring the claims against or equity interests in the Debtor should evaluate the financial information in light of the purposes for which it was prepared. The Debtor and its advisors are not liable for and undertake no responsibility to indicate variations from securities laws in the MOR or for any evaluations of the Debtor, including of their financial condition, based on this financial information or any other information.


Debtor in Possession Financing

On June 25, 2026, the Court entered the Interim Order (A) Authorizing the Debtor to Obtain Postpetition Financing, (B) Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay, (D) Scheduling Final Hearing, and (E) Granting Related Relief [Docket No. 63] (the “Initial Interim DIP Order”) authorizing the Debtor to enter into a senior secured superpriority debtor-in-possession term loan facility (the “Initial DIP Facility”). Prior to the Reporting Period, the Debtor drew $10,500,000 under the Initial DIP Facility. Please refer to the motion [Docket No. 10] seeking entry of the Initial Interim DIP Order for additional information regarding the Initial DIP Facility.

On July 23, 2026, the Court entered the Interim Order (A) Authorizing the Debtor to Obtain Replacement Postpetition Financing, (B) Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay, (D) Scheduling Final Hearing, and (E) Granting Related Relief [Docket No. 176] (the “Replacement Interim DIP Order”), which among other things, authorized the Debtor to enter into a senior secured superpriority debtor-in-possession term loan facility (the “Replacement DIP Facility”) to replace the Initial DIP Facility. During the Reporting Period, the Debtor incurred $18 million in DIP Obligations (as defined in the Replacement DIP Order) under the Replacement DIP Order, $11,432,958 of which was paid by the Debtor or on the Debtor’s behalf to satisfy all outstanding obligations arising under the Initial DIP Facility, including all fees. Please refer to the motion [Docket No. 161] seeking entry of the Replacement Interim DIP Order for additional information regarding the Replacement DIP Facility.

Payment of Prepetition Claims Pursuant to First Day Orders

Pursuant to certain interim orders of the Court entered on or about June 24, 2026 and final orders of the Court entered on or about July 21, 2026 (the “First Day Orders”), the Debtor is authorized (but not directed) to pay, among other things, certain prepetition claims of employees and taxing authorities. Accordingly, these liabilities may have been or may be satisfied in accordance with such First Day Orders. To the extent any payments were made on account of prepetition claims following the Petition Date pursuant to the authority granted to the Debtor under the First Day Orders, such payments have been included in the MOR (subject to the notes and statements and limitations provided herein).

Reservation of Rights

The Debtor reserves all rights to amend or supplement the MOR in all respects, as may be necessary or appropriate. Nothing contained in the MOR shall constitute a waiver of any of the Debtor’s rights or an admission with respect to any claim against the Debtor or otherwise in connection with this chapter 11 case

Specific MOR Disclosures

Part 1: Cash Receipts and Disbursements

Pursuant to the Initial Interim DIP Order and Replacement Interim DIP Order (together the “Interim DIP Orders”), fees and expenses of estate professionals were placed into the Professional Fees Account (as defined in the Interim DIP Orders) maintained by the Debtor. The transfer of such funds to the Professional Fee Account were treated as a transfer between Debtor accounts, and, therefore, were not treated as a distribution in Part 1(c). Professional fees will be treated as a disbursement in the reporting period in which they are paid to the applicable professionals.


Similarly, pursuant to the interim and final orders approving, among other things, the Debtor’s proposed form of adequate assurance of payment to utility companies [Docket No. 56 & 142] (the “Utilities Orders”), the Debtor deposited funds into the Utility Deposit Account (as defined in the Utilities Orders) maintained by the Debtor prior to the Reporting Period. The funds in such account will be treated as disbursements only if they are ultimately paid to a third party.

Notes to Part 2: Asset and Liability Status

Unless otherwise noted, all asset and liability information included in the MOR reflects net book value, which may differ from current market value. As set forth above, this information has not been subjected to procedures that would typically be applied to financial information presented in accordance with U.S. GAAP or any other recognized financial reporting framework. If such procedures were applied, the Debtor believes that the financial information presented in the MOR could be subject to change, including material change. Asset and liability information includes intercompany claims and other assets and liabilities which may not be settled in cash.

The Debtor continues to pay postpetition invoices on account of postpetition goods provided and services rendered in the ordinary course of business.

Given the Petition Date did not occur at month end, certain prepetition and postpetition liability balances are estimated. The Debtor has sought to assign liabilities to the prepetition and postpetition periods based on the information available as of and at the time the MOR was prepared. As additional information becomes available, the allocation of liabilities between prepetition and postpetition periods may change. The Debtor reserves the right to amend the balances as it deems appropriate and any such amendments will be reflected in future MORs

The amounts listed as “Prepetition Secured Debt,” “Prepetition Priority Debt” and “Prepetition Unsecured Debt” are preliminary and are subject to ongoing review and reconciliation by the Debtor. All amounts and classifications are subject to material adjustments.

Regarding Part 2c, the Debtor does not hold inventory; therefore, no inventory valuation method is applicable.

Notes to Part 6: Postpetition Taxes

Regarding Part 6c and 6d, postpetition employer payroll taxes accrued and paid include both the employer and employee portions of payroll taxes.

Notes to Part 7: Questionnaire

Regarding Part 7a, and as mentioned above, the Debtor is authorized to pay certain prepetition claims and obligations pursuant to the First Day Orders.


Regarding Part 7g, the Debtor incurred $18 million in DIP Obligations under the Replacement DIP Facility during the Reporting Period. The DIP Obligations were paid by the Debtor or on the Debtor’s behalf to pay all outstanding obligations under the Initial DIP Facility and to fund the Debtor’s business operations and its chapter 11 case.


UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

 

Sangamo Therapeutics, Inc.    Case No: 26-10989
Schedule of Post-Petition Borrowing Activity    Reporting Period: July 1, 2026 – July 31, 2026

 

 

The Debtor hereby submits this attestation regarding postpetition borrowing during the period of July 1, 2026 through July 31, 2026.

In accordance with the Interim Order (A) Authorizing the Debtor to Obtain Replacement Postpetition Financing, (B) Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay, (D) Scheduling Final Hearing, and (E) Granting Related Relief [Docket No. 176] (the “Replacement Interim DIP Order”), the Debtor incurred $18 million in DIP Obligations under the Replacement DIP Facility (each as defined in the Replacement Interim DIP Order) during the Reporting Period.

 

/s/ Nikunj Jain

    

October 23, 2026

Signature of Authorized Individual          Date

Nikunj Jain

    

Interim Chief Financial Officer

Printed Name of Authorized Individual      Title of Authorized Individual


UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

 

Sangamo Therapeutics, Inc.    Case No: 26-10989
Schedule of Payments on Prepetition Debt    Reporting Period: July 1, 2026 – July 31, 2026

 

 

All payments made by the Debtor during the Reporting Period (and included in the disbursements reported in this MOR) were authorized under various final orders granted by the Court, which authorized the Debtor’s various motions that were filed following the commencement of the chapter 11 case.

 

/s/ Nikunj Jain

    

October 23, 2026

Signature of Authorized Individual          Date

Nikunj Jain

    

Interim Chief Financial Officer

Printed Name of Authorized Individual      Title of Authorized Individual


UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

 

Sangamo Therapeutics, Inc.    Case No: 26-10989
Part 7(b) and 7(h) Payments Without Court Approval    Reporting Period: July 1, 2026 – July 31, 2026

 

 

Payments made by the Debtor to Rothwell, Figg, Ernst & Manbeck, P.C. and Daijogo & Pedersen, LLP were inadvertently made prior to such firm’s retention as ordinary course professionals in accordance with the OCP Order [Docket No. 202].

 

/s/ Nikunj Jain

    

October 23, 2026

Signature of Authorized Individual          Date

Nikunj Jain

    

Interim Chief Financial Officer

Printed Name of Authorized Individual      Title of Authorized Individual


UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

 

Sangamo Therapeutics, Inc.    Case No: 26-10989
Schedule of Payments to Insiders    Reporting Period: July 1, 2026 – July 31, 2026

 

 

The Debtor hereby submits this attestation regarding payments to insiders during the period of July 1, 2026 through July 31, 2026.

With respect to insiders, all cash payments made were on account of ordinary course salaries and authorized travel and expense reimbursements.

No non-cash transfers were made during this reporting period.

 

/s/ Nikunj Jain

    

October 23, 2026

Signature of Authorized Individual          Date

Nikunj Jain

    

Interim Chief Financial Officer

Printed Name of Authorized Individual      Title of Authorized Individual


UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

 

Sangamo Therapeutics, Inc.    Case No: 26-10989
All bank statements and bank reconciliations for the reporting period    Reporting Period: July 1, 2026 – July 31, 2026

 

 

The Debtor hereby submits this attestation regarding bank account reconciliations in lieu of providing copies of bank statements, bank reconciliations, and journal entries.

The Debtor’s standard practice is to ensure that bank reconciliations are completed as part of the month end close each reporting period. I attest that each of the Debtor’s bank accounts has been reconciled in accordance with their standard practices.

 

/s/ Nikunj Jain

    

October 23, 2026

Signature of Authorized Individual          Date

Nikunj Jain

    

Interim Chief Financial Officer

Printed Name of Authorized Individual      Title of Authorized Individual


Sangamo Therapeutics Inc.

 

MOR #2 - Statement of cash receipts and disbursements

Units (i.e. $ in 000s)

 

     07/01/2026 -
07/31/2026
 

Receipts

  

Receipts

   $ 59  

DIP Draw

   $ 18,000  
  

 

 

 

Total Receipts

   $ 18,059  

Operational Disbursements

  

Payroll & Benefits

   $ 1,747  

Rent & Facilities

     1,348  

Program Costs

     319  

International Operations

     416  

Other Operating Disbursements

     271  
  

 

 

 

Total Operational Disbursements

   $ 4,101  

Restructuring Disbursements

  

Professional Fees

     —   

US Trustee Fees

     —   

DIP Interest & Fees

     933  

DIP Repayments

     10,500  
  

 

 

 

Total Restructuring Disbursements

   $ 11,433  

Net Cash Flow

   $ 2,525  

Cash, cash equivalents, and restricted cash, beginning of period

   $ 14,382  
  

 

 

 

Cash, cash equivalents, and restricted cash, end of period

   $ 16,907  
  

 

 

 

 

1 of 4


Sangamo Therapeutics Inc.

 

MOR #2 - Balance sheet

Units (i.e. $ in 000s)

 

     As of  
     6/30/2026     7/31/2026  

Assets

    

Cash, Cash Equivalents and Restricted Cash

   $ 14,382     $ 16,910  

Accounts Receivables

     500       500  

Other Current Assets

     3,303       2,977  

Inventory

     —        —   

I/C Receivables - Current

     —        —   
  

 

 

   

 

 

 

Total Current Assets

   $ 18,186     $ 20,387  

Property, Plant & Equipment (Net)

   $ 9,644     $ 9,430  

Right of Use Assets

     2,747       2,694  

Other Non-Current Assets

     779       779  

Investments in Subsidiaries

     115,762       115,762  

I/C Receivables - Non-Current

     5,970       6,067  
  

 

 

   

 

 

 

Total Non-Current Assets

   $ 134,902     $ 134,731  
  

 

 

   

 

 

 

Total Assets

   $ 153,087     $ 155,118  
  

 

 

   

 

 

 

Liabilities and Stockholders’ Equity

    

A/P and Accrued Liabilities

   $ 30,620     $ 36,735  

Compensation and Benefits Liabilities

     13,304       17,304  

DIP Loan Payables

     10,500       18,000  

Other Current Liabilities1

     9,001       8,713  

I/C Payables - Current

     42,651       42,687  

Other Non-Current Liabilities1

     23,678       23,240  

I/C Payables - Non-Current

     692       703  

Non-Current Portion of Long-Term Debt

     —        —   
  

 

 

   

 

 

 

Total Liabilities

   $ 130,446     $ 147,383  

Stock

   $ 1,643,342     $ 1,643,342  

Retained Earnings

     (1,564,836 )      (1,564,836 ) 

Other Equity

     (30 )      (30 ) 

Net Income

     (55,834 )      (70,741 ) 

Total Stockholders’ Equity

   $ 22,642     $ 7,735  
  

 

 

   

 

 

 

Total Liabilities and Stockholders’ Equity

   $ 153,087     $ 155,118  
  

 

 

   

 

 

 

Notes:

 

1

Includes Deferred Revenues and Lease Liabilities

 

2 of 4


Sangamo Therapeutics Inc.

 

MOR #2 - Statement of operations (profit or loss statement)

Units (i.e. $ in 000s)

 

     07/01/2026 -
07/31/2026
 

Total Revenue

   $ 720  

COGS

     —   
  

 

 

 

Gross Profit

   $ 720  

Personnel & Staffing Costs1

   $ 1,931  

R&D Expenses2

     3,184  

Selling Expenses

     —   

General and Administrative Expenses

     863  

Facilities & OH Expenses1

     972  

I/C Expenses2

     28  

Other Expenses2

     19  

Interest Expense

     105  

Restructuring Expenses3

     4,244  

Depreciation and/or amortization

     216  
  

 

 

 

Total Operating Expenses

   $ 11,562  

Unrealized FX (Gain)/Loss

   $ 336  

Non-Operating (Income)/Expense

     (12 ) 
  

 

 

 

Total Non-Operating (Income)/Expense

   $ 323  
  

 

 

 

Net Profit/(Loss) for the Period

   ($ 11,165 ) 
  

 

 

 

Notes:

 

1

Considered under “General and Administrative Expenses” for MOR

2

Considered under “Other Expenses” for MOR

3

Includes professional fees and DIP loan fees accruals

 

3 of 4


Sangamo Therapeutics Inc.

 

MOR #2 - Detailed explanations

Part 2 - Question C - Inventory

Sangamo does not hold inventory; therefore, no inventory valuation method is applicable

Part 7 - Question G - Was there any postpetition borrowing, other than trade credit?

 

Detail

   Date     

Payee/Lender Name

   Amount  

DIP Replacement - Future Solutions Invenstment

     7/24/2026      Future Solution Investments LLC    $ 18,000,000  

 

4 of 4


Miscellaneous:

26-10989-CTG Sangamo Therapeutics, Inc.

 

Type: bk    Chapter: 11 v    Office: 1 (Delaware)
Assets: y    Judge: CTG   

Case Flag: CLMSAGNT, LeadSC, PlnDue, DsclsDue, STANDOrder, SealedDoc(s)

U.S. Bankruptcy Court

District of Delaware

Notice of Electronic Filing

The following transaction was received from James McCauley entered on 10/23/2026 at 12:33 PM EDT and filed on 10/23/2026

 

Case Name:   Sangamo Therapeutics, Inc.
Case Number:   26- 10989-CTG
Document Number:   537

Docket Text:

Amended Chapter 11 Monthly Operating Report for the Month Ending: 07/31/2026 (related document(s)[427]) Filed by Sangamo Therapeutics, Inc.. (McCauley, James)

The following document(s) are associated with this transaction:

Document description: Main Document

Original filename: SGMO - July 2026 MOR [AMENDED]. pdf

Electronic document Stamp:

[STAMP bkecfStamp_ID=983460418 [Date=10/23/2026] [FileNumber=20049499-

0] [11 553d83764abea0bc846f63b121877f75bdf5cf7446f5ff90d993f070d73eec6a

4de2e06f9b7441c242c2714f7cd0e0554586255ef2836d209d30badcd0adee]]

26-10989-CTG Notice will be electronically mailed to:

Jacob A. Adlerstein on behalf of Interested Party Eli Lilly and Company

jadlerstein@paulweiss.com

Elihu Ezekiel Allinson, III on behalf of Interested Party Shire Human Genetic Therapies, Inc.

ZAllinson@SHA-LLC.com, ecf@williamdsullivanllc.com; hcoleman@sha-llc.com

Olya Antle on behalf of Debtor Sangamo Therapeutics, Inc.

oantle@cooley.com, efilingnotice@cooley.com;efiling-notice@ecf.pacerpro.com

Joseph N. Argentina, Jr. on behalf of Creditor VWR International, LLC

joseph. argentina@faegredrinker.com, cathy.greer@faegredrinker.com

Darren Azman on behalf of Creditor Committee Official Committee of Unsecured Creditors of Sangamo Therapeutics, Inc. dazman@mcdermottlaw.com

Joshua Brooks on behalf of Interested Party PTC Therapeutics, Inc.

brooks@lrclaw.com, ramirez@lrclaw.com;huynh@lrclaw.com;hitchens@lrclaw.com;ford@lrclaw.com;kittinger@lrclaw.com

Kate R. Buck on behalf of Interested Party Astellas Gene Therapies, Inc.

kbuck@mccarter. com

Linda J. Casey on behalf of U.S. Trustee U.S. Trustee

Linda.Casey@usdoj.gov

Austin Chavez on behalf of Interested Party PTC Therapeutics, Inc.

austin.chavez@wilmerhale.com, Mike.McGuinness@wilmerhale.com

Shawn M. Christianson on behalf of Creditor Oracle America, Inc.

schristianson@buchalter.com, cmcintire@buchalter.com

James A. Copeland on behalf of Interested Party Northridge ATM, LLC

james.copeland@nortonrosefulbright.com

Kristin Cunningham on behalf of Debtor Sangamo Therapeutics, Inc.

cunningham@rlf.com, rbgroup@rlf.com; rebecca--speaker-6328@ecf.pacerpro.com

Daniel J. DeFranceschi on behalf of Debtor Sangamo Therapeutics, Inc.

defranceschi@rlf.com, RBGroup@rlf.com;ann-jerominski-2390@ecf.pacerpro.com;rebecca--speaker-6328@ecf.pacerpro.com

Robert J. Dehney on behalf of Interested Party Eli Lilly and Company

rdehney@morrisnichols.com, robert-dehney-4464@ecf.pacerpro.com;jlawrence@morrisnichols.com;john-lawrence-

0804@ecf.pacerpro.com;rchevli@morrisnichols.com;radha--chevli--2257@ecf.pacerpro.com

Brenna Anne Dolphin on behalf of Interested Party Eli Lilly and Company

bdolphin@morrisnichols.com, brenna-dolphin-9491@ecf.pacerpro.com;john-lawrence-

0804@ecf.pacerpro.com;jlawrence@morrisnichols.com;rchevli@morrisnichols.com;radha--chevli--2257@ecf.pacerpro.com

Andrew C. Ehrmann on behalf of Interested Party Northridge ATM, LLC